Cargando…
Cancer antigen 125 in ovarian cancer surveillance: a decision analysis model
We used decision analysis techniques with Markov cohort modeling to examine the role of cancer antigen 125 (CA-125) in follow-up surveillance strategies among patients with advanced ovarian cancer. Utilities were derived from a societal perspective. Using quality-adjusted life years (qalys) as the o...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Multimed Inc.
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2002486/ https://www.ncbi.nlm.nih.gov/pubmed/17938699 |
_version_ | 1782135719585644544 |
---|---|
author | Hopkins, M.L. Coyle, D. Le, T. Fung, M. Fung Kee Wells, G. |
author_facet | Hopkins, M.L. Coyle, D. Le, T. Fung, M. Fung Kee Wells, G. |
author_sort | Hopkins, M.L. |
collection | PubMed |
description | We used decision analysis techniques with Markov cohort modeling to examine the role of cancer antigen 125 (CA-125) in follow-up surveillance strategies among patients with advanced ovarian cancer. Utilities were derived from a societal perspective. Using quality-adjusted life years (qalys) as the outcome variable, the value of CA-125 monitoring for asymptomatic women with ovarian cancer was found to be reduced as compared with a strategy that includes CA-125 testing. Decisions to include CA-125 in surveillance strategies for ovarian cancer patients should be made after discussion with full disclosure of the preference-sensitive nature of CA-125. The model demonstrates that preferences and perspective can influence decisions in cancer care. |
format | Text |
id | pubmed-2002486 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | Multimed Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-20024862007-10-15 Cancer antigen 125 in ovarian cancer surveillance: a decision analysis model Hopkins, M.L. Coyle, D. Le, T. Fung, M. Fung Kee Wells, G. Curr Oncol Practice Guideline Series We used decision analysis techniques with Markov cohort modeling to examine the role of cancer antigen 125 (CA-125) in follow-up surveillance strategies among patients with advanced ovarian cancer. Utilities were derived from a societal perspective. Using quality-adjusted life years (qalys) as the outcome variable, the value of CA-125 monitoring for asymptomatic women with ovarian cancer was found to be reduced as compared with a strategy that includes CA-125 testing. Decisions to include CA-125 in surveillance strategies for ovarian cancer patients should be made after discussion with full disclosure of the preference-sensitive nature of CA-125. The model demonstrates that preferences and perspective can influence decisions in cancer care. Multimed Inc. 2007-10 /pmc/articles/PMC2002486/ /pubmed/17938699 Text en 2007 Multimed Inc. |
spellingShingle | Practice Guideline Series Hopkins, M.L. Coyle, D. Le, T. Fung, M. Fung Kee Wells, G. Cancer antigen 125 in ovarian cancer surveillance: a decision analysis model |
title | Cancer antigen 125 in ovarian cancer surveillance: a decision analysis model |
title_full | Cancer antigen 125 in ovarian cancer surveillance: a decision analysis model |
title_fullStr | Cancer antigen 125 in ovarian cancer surveillance: a decision analysis model |
title_full_unstemmed | Cancer antigen 125 in ovarian cancer surveillance: a decision analysis model |
title_short | Cancer antigen 125 in ovarian cancer surveillance: a decision analysis model |
title_sort | cancer antigen 125 in ovarian cancer surveillance: a decision analysis model |
topic | Practice Guideline Series |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2002486/ https://www.ncbi.nlm.nih.gov/pubmed/17938699 |
work_keys_str_mv | AT hopkinsml cancerantigen125inovariancancersurveillanceadecisionanalysismodel AT coyled cancerantigen125inovariancancersurveillanceadecisionanalysismodel AT let cancerantigen125inovariancancersurveillanceadecisionanalysismodel AT fungmfungkee cancerantigen125inovariancancersurveillanceadecisionanalysismodel AT wellsg cancerantigen125inovariancancersurveillanceadecisionanalysismodel |